Actively Recruiting

Phase 3
Age: 3Months - 50Years
All Genders
NCT05534672

Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex

Led by Katarzyna Kotulska · Updated on 2023-08-08

200

Participants Needed

2

Research Sites

227 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the RaRE-TS study is to determine safety, tolerability and efficacy of rapamycin versus placebo in a drug resistant epilepsy associated with tuberous sclerosis complex (TSC).

CONDITIONS

Official Title

Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex

Who Can Participate

Age: 3Months - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged from 3 months up to 50 years at the day of randomization
  • Patients, parents, or caregivers willing and able to provide informed consent
  • Patients, parents, or caregivers willing and able to follow all study requirements
  • Definite diagnosis of tuberous sclerosis complex according to Consensus criteria (Northrup, 2013)
  • Drug-resistant epilepsy associated with TSC with at least 8 seizures during 4 weeks
Not Eligible

You will not qualify if you...

  • Treatment with mTOR inhibitor within 3 months prior to screening
  • History of pseudo-epileptic seizures
  • History of progressive central nervous system disease other than TSC
  • Surgery within 2 weeks prior to screening
  • Severe infection within 2 weeks prior to screening
  • Use of cannabis derivatives
  • Contraindications for MRI or general anesthesia
  • Serious comorbidities that pose significant risk or may affect study results as judged by the investigator
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Medical University of Lodz

Lodz, Poland, 90-419

Not Yet Recruiting

2

Children's Memorial Health Institute, Neurology and Epileptology

Warsaw, Poland, 04-730

Actively Recruiting

Loading map...

Research Team

K

Katarzyna Kotulska-Jozwiak

CONTACT

M

Monika Szkop

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here